Clinical Policy: Transcatheter Closure of Patent Foramen Ovale

Description
Patent foramen ovale (PFO) is a congenital cardiac lesion which is generally asymptomatic and affects up to a quarter of the population. PFO can present with an array of significant clinical complications, including cryptogenic stroke. This policy describes the medical necessity requirements for the percutaneous transcatheter closure of a patent foramen ovale with the Amplatzer™ PFO Occluder.

Policy/Criteria
I. It is the policy of Pennsylvania Health and Wellness® (PHW) that the percutaneous transcatheter closure of PFO with the Amplatzer PFO Occluder is medically necessary to reduce the risk of recurrent ischemic stroke for the following indications:
   A. Age ≥ 18 and ≤ 60;
   B. Both a neurologist and a cardiologist confirm all of the following:
      1. PFO with a right-to-left interatrial shunt detected by bubble study;
      2. Cryptogenic stroke caused by a presumed paradoxical embolism;
      3. Absence of other risk factors of ischemic stroke, including any of the following:
         a. Atherosclerosis;
         b. Small vessel occlusion.
         c. Hypercoagulable state;
         d. Atrial fibrillation;
         e. Arterial dissection.
         f. Hypercoagulable state;
         g. Atrial fibrillation;
         h. Arterial dissection.
   4. None of the following contraindications:
      a. Intra-cardiac mass, vegetation, tumor or thrombus at the intended site of implant, or documented evidence of venous thrombus in the vessels through which access to the PFO is gained;
      b. Vasculature through which access to the PFO is gained is inadequate to accommodate the appropriate sheath size;
      c. Anatomy in which the Amplatzer PFO device size required would interfere with other intracardiac or intravascular structures, such as valves or pulmonary veins;
      d. Other source of right-to-left shunts, including an atrial septal defect and/or fenestrated septum;
      e. Active endocarditis or other untreated infections.

II. It is the policy of PHW® that the percutaneous transcatheter closure of PFO is experimental/investigational for the following:
   A. Devices not currently FDA-approved for PFO, including any of the following:
      1. CardioSEAL STARFlex Septal Closure System;
Background
The foramen ovale is a particular structure of the fetal circulation that fails to close and is present in 25% of the adult population, forming a PFO.\textsuperscript{1,2} The biological significance of PFOs have been widely debated in the literature for the last decade. Case control studies have established an association between an increased risk of ischemic stroke and the PFO.\textsuperscript{1} Three initial randomized controlled trials (e.g. the CLOSURE I study, the PC study, and the RESPECT study), as well as a meta-analysis of 14 trials, collectively demonstrate that there is no significant advantage for surgical PFO closure to improve ischemic stroke prevention over medical therapy.\textsuperscript{7-10}

However, four more recently published articles in \textit{The New England Journal of Medicine} expand the body of work and extend analyses.\textsuperscript{2-6} Mas \textit{et al.} for the CLOSE investigators assessed 663 patients and demonstrated reduced recurrent stroke rates after PFO closure compared to oral anticoagulation with antiplatelet medical therapy in patients with cryptogenic stroke.\textsuperscript{2} This finding was also validated by Søndergaard for the Gore REDUCE investigators in their analysis of 664 patients\textsuperscript{4}. Furthermore, Saver \textit{et al.} for the RESPECT investigators recapitulate earlier results in a multicenter trial, noting that closure of PFO was associated with a lower rate of recurrent ischemic stroke, after having followed 980 patients for a median of 5.9 years.\textsuperscript{3}

The 2014 American Heart Association / American Stroke Association have not yet been updated to include recent randomized controlled trials (RCTs), and the 2016 Practice Advisory Board of the American Academy of Neurology, does not recommend percutaneous transcatheter closure of PFO outside of research settings.\textsuperscript{11-12} The American Heart Association published a 2018 review that stated that recent RCTs have demonstrated the superiority of PFO closure over pharmacological treatment in reducing risk of recurrent ischemic stroke in certain patients, and that governing societies should rewrite their guidelines accordingly.\textsuperscript{15}

Coding Implications
This clinical policy references Current Procedural Terminology (CPT\textsuperscript{®}). CPT\textsuperscript{®} is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2018, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.
**CLINICAL POLICY**

**Transcatheter Closure of Patent Foramen Ovale**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>93580</td>
<td>Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1817</td>
<td>Septal defect implant system, intracardiac</td>
</tr>
</tbody>
</table>

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q21.1</td>
<td>Atrial septal defect</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Policy developed</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Added “but not limited to” to criteria regarding absence of other risk factors for ischemic stroke. Added hypercoagulation, arterial dissection, and atrial fibrillation as conditions that must be ruled out. Added contraindications per instruction manual. Updated background.</td>
<td>09/18</td>
<td>12/18 01/28/18</td>
</tr>
</tbody>
</table>

**References**

CLINICAL POLICY
Transcatheter Closure of Patent Foramen Ovale

